



Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg
Worli, Mumbai – 400 030. India
Tel. : + 91 22 6663 5456
Fax : + 91 22 6663 5460
Email : auro@aurolabs.com
Web : www.aurolabs.com
Reg. Off / Mfg. Unit :
K-56, M.I.D.C. Tarapur,
Dist. Palghar, Maharashtra – 401506
CIN No. L33125MH1989PLC051910

August 23, 2023

The Listing Department
BSE Limited
Phiroz Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

Scrip ID/Code : 530233
Subject : Intimation regarding Capacity expansion
Ref : Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Dear Sir/Madam,

We are writing to inform you in accordance with the provisions of Regulation 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors of the Company, at their meeting held today, August 23, 2023, have approved a capacity expansion in the existing unit of the Company. The required information as per SEBI Circular dated 13th July, 2023 is detailed hereunder:

Particulars	Details
Existing Capacity	Metformin HCL - 1800 MT / P. A
Existing capacity Utilisation	Metformin HCL - 1200 MT / P. A.
Proposed Capacity Utilisation	Metformin HCL - 3600 MT / P. A.
Period within which the proposed Capacity is to be added	31 st March 2024
Investment required	40.00 cr. Approx.
Mode of Financing	Internal Accruals and Term Loan from Bank
Rationale	The product Metformin HCL is expected to have significant demand in the near future with a growth rate of over 10% worldwide in Type 2 Diabetes disease.

The meeting of the Board of Directors commenced at 02.00 PM and concluded at 04.00 PM.

This intimation is also being uploaded on Company's website at www.aurolabs.com. Kindly take the above on your record.

Thanking you,
Yours Faithfully,
For, Auro Laboratories Limited

(Siddhartha Deorah)
Whole Time Director
DIN: 00230796